CytomX Therapeutics (CTMX) Non-Current Assets (2014 - 2026)

CytomX Therapeutics' Non-Current Assets history runs 13 years deep, the most recent figure standing at $6.3 million for Q1 2026.

• Quarterly Non-Current Assets fell 47.24% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.4 million (down 40.43% YoY) and the FY2025 annual result came in at $7.6 million, down 42.21% from the prior year.
• Non-Current Assets was $6.3 million for Q1 2026 at CytomX Therapeutics, down from $7.6 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $28.4 million in Q1 2022 and bottomed at $6.3 million in Q1 2026.
• A 5-year average of $17.4 million and a median of $17.4 million in 2024 frame the typical range for Non-Current Assets.
• Peak annual rise in Non-Current Assets reached 16.89% in 2022, while the deepest fall reached 79.87% in 2022.
• CytomX Therapeutics' Non-Current Assets stood at $23.8 million in 2022, then slipped by 20.74% to $18.9 million in 2023, then slipped by 29.85% to $13.2 million in 2024, then tumbled by 42.21% to $7.6 million in 2025, then slipped by 18.09% to $6.3 million in 2026.
• Business Quant data shows CTMX's Non-Current Assets at $6.3 million in Q1 2026, $7.6 million in Q4 2025, and $9.0 million in Q3 2025.